WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM
WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM Morrisville, NC, USA & London, UK – June 20, 2023 – WEP Clinical LTD (WEP), a specialist [...]
